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identify the value of MPV as a prognostic factor of throm-
bosis recurrence in patients with APS.
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Introduction
Antiphospholipid antibody syndrome (APS) is an acquired 
thrombophilic condition associated with venous and/or 
arterial thrombosis and/or pregnancy morbidity with the 
presence and persistence of antiphospholipid antibodies 
(Abs). The average population prevalence of Abs in asymp-
tomatic subjects ranges from 1 to 5.6 % [1, 2]. The labora-
tory diagnosis of APS is based on tests identifying the pres-
ence of Abs such as anti-β2 glycoprotein-I (anti-β2GPI) 
antibodies, anticardiolipin (aCL) antibodies or lupus anti-
coagulant (LA) on two or more occasions at least 12 weeks 
apart [3].
Although the mechanism of thrombosis in patients with 
Abs is not completely known, several mechanisms have 
been proposed including Abs interference with endogenous 
anticoagulant mechanisms (i.e. disruption of the annexin 
A5 activity, inhibition of the protein C pathway), interact-
ing with endothelial cells and inducing increased expres-
sion of adhesion molecules and tissue factor or activation 
of the complement cascade. Increasing platelet activation, 
adhesion and aggregation play important roles in a pro-
thrombotic state [4–6]. Additionally, recurrent thrombosis 
is observed only in some patients with APS, which may 
suggest different mechanisms of hypercoagulable processes 
in different patients.
One of the currently discussed mechanisms related to a 
high risk of thromboembolism is increased mean platelet 
Abstract Increased mean platelet volume (MPV) is asso-
ciated with platelet reactivity and is a predictor of cardio-
vascular risk and unprovoked venous thromboembolism. 
The aim of our study was to evaluate MPV in patients with 
confirmed antiphospholipid antibody syndrome (APS) and 
to identify the correlation between the value of MPV and 
the recurrence of thrombosis. The studied group consists of 
247 patients with a history of thrombosis and/or pregnancy 
loss (median age 38, range 18–66 years) classified as APS 
group (n = 70) or APS negative patients (n = 177) accord-
ing to the updated Sapporo criteria. The control group con-
sisted of 98 healthy subjects. MPV was significantly higher 
in the group of patients with clinically and laboratory 
confirmed APS (median 7.85, range 4.73–12.2 fl) in com-
parison with the controls. It was also higher than in APS 
negative patients (7.61, range 5.21–12.3 fl). APS patients 
with triple positivity for antiphospholipid antibodies with 
respect to Miyakis classification categories had higher 
MPV values than other APS patients (9.69 ± 1.85 vs. 
7.29 ± 1.3 fl, p = 0.001). Recurrent thrombotic episodes 
were observed in 83 patients, but among the triple positive 
high-risk patients with APS in 80 % cases (p = 0.0046). In 
receiver operating characteristic curve analysis, the value of 
MPV level for thrombosis recurrence prediction in the APS 
group with sensitivity of 86 % and specificity of 82 % was 
7.4 fl. In the multivariate logistic regression model, MPV 
above 7.4 fl (OR 3.65; 95 % CI 1.38–9.64, p = 0.009) 
significantly predicts thrombosis recurrence. Our results 
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volume (MPV), as has been reported in meta-analysis and 
prospective studies [7, 8].
Therefore, the question arises whether MPV is directly 
or indirectly connected with thrombosis occurrence in 
APS patients. To our knowledge, little is known about the 
value of MPV and its prognostic significance for thrombo-
sis recurrence in patients with confirmed antiphospholipid 
syndrome.
The aim of this study was to evaluate and compare MPV 
in patients diagnosed with APS to patients with thrombotic 
complications without APS or healthy controls and to iden-
tify the correlation between the value of MPV and throm-
bosis recurrence.
Methods
A total number of 247 patients with a history of throm-
botic episodes and/or pregnancy loss were analysed 
between 2009 and 2012. All patients were white Cau-
casians with median age 38 (range 18–66) years. For all 
patients, demographical data, clinical risk factors for arte-
rial and venous thrombosis and smoking status were ana-
lysed (Table 1). Patients with malignancy were excluded 
from the analyses.
APS and other hereditary thrombophilia tests were 
performed on all studied patients. For coagulation tests, 
patients were recruited at least 6 months after a thrombotic 
event and at least 4 weeks after anticoagulation with vita-
min K antagonists had been discontinued.
For APS, LA, measurement of IgG and IgM aCL anti-
bodies and anti-β2 glycoprotein-I (aβ2GPI) were per-
formed according to the updated Sapporo classification 
criteria with respect to the manufacturer’s recommenda-
tions (Siemens Healthcare Diagnostics Products GmbH, 
Marburg, Germany). Cardiolipin and anti-β2 glycoprotein-I 
antibodies assays were calibrated against Sapporo Standard 
(INOVA Diagnostics, San Diego, USA).
Additional thrombophilia tests included deficiencies of 
antithrombin, protein C and protein S, activated protein C 
resistance assays (APCr-PCA ratio) and increased plasma 
level of factor VIII (Helena Biosciences Europe, UK, 
Gateshead). Factor V Leiden G1691A and prothrombin 
G20210A polymorphisms were determined as described 
elsewhere [9, 10]. D-dimer and homocysteine were ana-
lysed by routine laboratory techniques using Siemens 
Healthcare Diagnostics Products.
To find the influence of MPV on thrombosis risk and 
thrombosis recurrence, this parameter was analysed in the 
APS patients and in the APS negative group, as well as in 
healthy subjects. The control group consisted of 98 age-
matched healthy subjects, median age 41 (range 20–63 years); 
60 % were male. None of them had personal history of VTE 
or arterial thrombosis (myocardial infarction or stroke).
For MPV estimation, a full blood count was performed 
on an automated analyser within 60 min of collection by a 
CELL-DYN 3700SL analyser using impedance technology 
(Abbott Diagnostics, Chicago, USA) [11]. Fasting blood 
samples were collected into vacuum tubes with minimal 
stasis (Sarstedt, Nümbrecht, Germany).
The Local Bioethical Committee approved this research 
protocol.
Statistical methods
The results are presented using methods of descriptive 
statistics such as frequency (n), arithmetic mean (x) and 
standard deviation (SD). The Shapiro–Wilk’s test was per-
formed to assess normality. In order to compare differences 
between the groups, the Chi-square test or Fisher’s exact 
test was used for categorical variables and the Mann–Whit-
ney U test for continuous variables. For variables with a 
normal distribution and homogeneous variances, the signif-
icance of differences between the groups was examined by 
analysis of variance followed by the Tukey’s post hoc test. 
For variables not normally distributed or of unequal vari-
ance, ANOVA analysis of variances followed by the non-
parametric Kruskal–Wallis’s test was applied.
Correlations between the individual parameters and 
MPV were calculated using the Spearman rank correla-
tion method. Multiple regression was performed to inves-
tigate which Abs caused high MPV in APS patients with 
triple positivity. The coefficient of determination was 
Table 1  Demographical and clinical characteristics of the studied 
patients
Characteristics n = 247
Age, years, median (range) 38 (18–66)
Sex, female/male (n) 160/87
Risk factors for venous thrombosis (n)
 Surgery, immobilization or trauma 12
 Immobilization or trauma 12
 Use of oral contraceptives or hormone replacement 
therapy
73
 Pregnancy or postpartum period until 6 weeks 16
 Family history 20
Risk factors for arterial thrombosis (n)




 Smoking habit 64
 Family history 35
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used to evaluate how well the model fits the obtained data 
(R-Square).
Receiver operating characteristic (ROC) analysis was 
performed to determine the sensitivity and specificity with 
95 % confidence intervals (CIs) at cut-off values for the 
MPV level predictive of thrombosis recurrence.
A multivariate logistic regression was used to evaluate 
potential risk factors that might influence thrombosis recur-
rence. In each model, the odds ratio (OR) for each inde-
pendent variable with a 95 % confidence interval (CI) was 
determined. A p value below 0.05 was regarded as statis-
tically significant. The statistical analyses were performed 
with STATISTICA 10 and STATISTICA Medical Package 
2.0 (StatSoft, Inc. 2013 software).
Results
Antiphospholipid antibody syndrome was diagnosed 
in 70 patients (median age 37 years, and 37 % of whom 
were male) in the absence of any underlying autoimmune 
disease. All of them fulfilled both clinical and laboratory 
criteria for APS diagnosis according to Miyakis [3] (APS 
patients). One hundred and seventy-seven patients with a 
history of thrombotic events, either venous thromboembo-
lism or arterial thrombosis, in whom the presence of Abs 
was not confirmed, were placed in the APS negative group 
(APS negative patients).
Of the 57 DVT episodes in the APS patients, 21 
(39.62 %) had proximal DVT alone, 14 (26.41 %) had 
symptomatic pulmonary embolism (PE), nine cases had 
DVT combined with PE and 20 cases were diagnosed with 
distal DVT. Among the patients with cerebral thrombotic 
episodes (n = 11), the most common were ischemic stroke/
transient ischemic attack (82 %). Pregnancy morbidity 
according to classification criteria for APS was recorded 
in ten women in the APS group [3]. Among women, a his-
tory of oral contraceptives was identified in 73 of all cases 
(45.6 %), ten in the APS group. Pregnancy/postpartum 
thrombotic complications were identified in 4 (9 %) of the 
APS women.
The main characteristics of patients and frequency of 
clinical thrombotic manifestations associated with APS are 
shown in the Table 2.
According to the Miyakis laboratory criteria, the APS 
patients were allocated to category I or category II on the 
basis of positivity to Abs [3]. Single test positivity was 
found in 48 cases, which constitute 68 % of APS patients, 
category IIA (only LA detection). Triple Abs positivity 
(category I) defined by the presence of LA and high titres 
of IgG or IgM aCL > 40 GPL/MPL and IgG or IgM anti-
β2GPI > 99th percentile antibodies was identified in ten 
patients with APS (14.28 %), while double positivity (also 
category I) in 12 cases of confirmed APS—17.14 %.
All three groups, the APS, the APS negative and the con-
trols did not differ with respect to age and platelet counts. 
MPV was significantly higher in the APS group (mean 
7.85, range 4.73–12.2 fl) in comparison with the controls 
(6.85, range 5.01–7.93 fl, p = 0.004). There was no differ-
ence in regard to MPV between the APS group (mean 7.85, 
range 4.73–12.2 fl) and the controls (6.85, range 5.01–
7.93 fl, p = 0.004), Table 3.
A significant positive correlation was found between the 
value of MPV and Abs titre, with the Spearman correlation 
coefficients of 0.018 (p = 0.0116) for the increased ratio of 
LA1/LA2 and 0.018 (p = 0.0082) for anti-β2 glycoprotein-
I. No significant correlation was evident between MPV and 
aCL antibodies.
Table 2  Clinical characteristics of the APS positive and negative patients
Characteristics n APS patients (n = 70) APS negative patients (n = 177) p value
Female/male gender (n) 160/87 44/26 116/61 0.852
Median age, years (range) 247 37.0 (18–66) 38.1 (18–65) 0.478
Type of thrombosis [no. (%)]
 Proximal deep vein thrombosis 105 21 (30.0) 84 (47.45) 0.007
 Pulmonary embolism 44 14 (20.0) 30 (16.95) 0.762
 Cerebral vein thrombosis/stroke 55 11 (15.4) 44 (24.86) 0.192
 Pregnancy loss 26 10/44 (22.72) 16/116 (13.79) 0.151
 Distal deep vein thrombosis 51 20 (28.57) 33 (18.64) 0.341
Inherited thrombophilia [no. (%)]
 Antithrombin deficiency 6 4 (5.71) 2 (1.1) 0.002
 Protein C deficiency 5 2 (2.86) 3 (1.7) 0.219
 Protein S deficiency 2 1 (1.43) 1 (0.56) 0.256
 Factor V G1691A 37 12 (17.14) 25 (14.12) 0.086
 Prothrombin G20210A 8 1 (1.43) 7 (3.95) 0.516
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With respect to MPV, a significantly higher MPV was 
found in patients with triple positivity for Abs in comparison 
with other Miyakis classification categories (9.69 ± 1.85 
vs. 7.29 ± 1.3 fl, p = 0.001), Fig. 1. The median platelet 
count was 230 (range 126–301 G/L) for the patients with 
triple positivity for Abs and 267 (range 123–418 G/L) for all 
the other APS patients. In multiple regression, the analysed 
parameters, including LA, aCL and aβ2GPI (IgG and IgM), 
had an effect on the value of MPV in patients with triple 
positivity for Abs. The model explained 85 % of the vari-
ability of MPV (F = 7.46, p < 0.0244). In this model, the 
ratio of LA1/LA2 and the level of aβ2GPI were proven to 
be statistically significant (p = 0.0203 and p = 0.0081). 
Cut-off value of MPV for prediction of thrombosis 
recurrence
The ROC analysis indicated a cut-off value of 7.4 fl 
for MPV with 86 % sensitivity and 82 % specificity 
(AUC = 0.863; p = 0.0001) for thrombosis recurrence pre-
diction (Fig. 2).
Factors affecting thrombosis recurrence
Recurrent thrombosis was observed in 83 patients of the 
studied cohort (n = 247). Among the APS positive patients, 
recurrent thrombotic episodes were recorded in 66.26 % 
(55/70). In 18 cases, multiple thrombotic events were pre-
sent. Venous thromboembolism recurrence was recorded 
in 42 cases (60 %), recurrence of arterial thrombosis in 11 
patients (15.71 %) and both in two patients (2.86 %) with 
confirmed APS, while in the APS patients with triple posi-
tivity for Abs, recurrent thrombotic events were recorded 
in ten cases (80 %, p = 0.0046). One patient died in the 
course of thrombosis recurrence complication, this patient 
was also a homozygous carrier of factor V Leiden G1691A 
mutation and had a history of both venous and arterial 
thrombotic episodes.
The risk-factor analysis for thrombosis recurrence 
in the APS group included age, male gender, history of 
Table 3  Characteristics of patients with or without APS, and the healthy controls
Values are expressed as mean x ± SD or percentage
PLT platelet count, MPV mean platelet volume
* Post hoc (APS positive patients vs. controls p = 0.002 and APS negative group vs. controls p ≤ 0.001)
Characteristics APS positive patients (n = 70) APS negative patients (n = 177) Controls (n = 98) p value
Age (years) 38.6 ± 13.8 40.2 ± 12.7 40.3 ± 12.6 0.677
Female/male (n) 44/26 116/61 37/61 0.001
Platelet parameters
 PLT (×109/L) 257.0 ± 68.4 227.2 ± 72.1 263.4 ± 55.9 0.219
 MPV (fl) 7.85 ± 1.81 7.61 ± 1.21 6.85 ± 0.71 <0.001*
Fig. 1  MPV levels in patients with triple Abs positivity and other 
Miyakis classification categories for APS
Fig. 2  ROC curve of MPV for thrombosis recurrence prediction in 
APS group. Area under the curve (AUC) 0.863. CI (95 %) 0.739–
0.988. SE 0.064
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PE, hereditary thrombophilia and the following labora-
tory parameters; MPV (≥7.4 fl), factor VIII activity and 
D-dimer level. Upon univariate analysis, MPV (≥7.4 fl), 
previous PE history and hereditary thrombophilia were the 
only factors significantly associated with the risk of throm-
bosis recurrence in our cohort. In the multivariate logistic 
regression model, only MPV above 7.4 fl (OR 3.65; 95 % 
CI 1.38–9.64, p = 0.009) significantly affected the risk of 
thrombosis recurrence in the APS group (Table 4).
Discussion
Among many mechanisms of thrombosis in patients with 
antiphospholipid syndrome, the pivotal role of platelets is 
well established. It is known that platelet activation and 
aggregation predispose to thrombotic events in patients 
with antiphospholipid syndrome [6]. There has been evi-
dence that Abs enhance platelet activation through the 
apolipoprotein ER2 receptor and therefore activate the 
p38 mitogen-activated protein kinase (p38MAPK) path-
way with phosphorylation of cytosolic phospholipase A2 
(cPLA2) ending in thromboxane B2 production, and this 
results in platelet aggregation, especially by increasing the 
expression of GPIIb–IIIa [12].
The platelet size, measured as MPV, reflects platelet 
reactivity, including aggregation, glycoprotein IIb-IIIa 
expression and production of more thrombogenic factors 
(thromboxane A2, platelet factor 4, β-thromboglobulin, 
P-selectin and platelet-derived growth factor) [11, 13, 
14]. The regulation of the platelet size is multifacto-
rial and independent of the age of platelets [8]. Evidence 
from meta-analysis and prospective studies indicated that 
an increased MPV is not only a predictor of unprovoked 
venous thromboembolism [7], but also a predictor of car-
diovascular risk including acute myocardial infarction, 
its mortality and restenosis following coronary angio-
plasty [8, 15]. Besides this, there are reports concerning 
the association between increased MPV and heart failure, 
arterial stiffness, acute PE, stroke prediction and mortality 
[16–19].
So far, little is known about the mean value of MPV in 
patients diagnosed with APS. The available data are incon-
sistent. In one report comparing two different haematologi-
cal analysers, lower MPV was recorded in 14.28 % and in 
65.71 % of cases with APS (n = 35), but a relation with 
thrombotic potency was not studied [20]. A more recent 
study, however, reported that among patients with thrombo-
cytopenia, five in nine patients with antiphospholipid syn-
drome had increased MPV [21].
To establish if MPV might be an indirect indicator of 
platelet activation in the APS, we analysed MPV in patients 
with confirmed antiphospholipid syndrome and in patients 
with thrombotic complication without APS, as well as in 
asymptomatic controls. In our cohort of patients, MPV was 
statistically significantly higher in the APS patients in com-
parison with the control subjects. It also tended to be higher 
in the APS group when compared with the APS negative 
group. A significantly positive correlation between LA and 
aβ2GPI for the value of MPV was observed in the APS 
group, but the reason for this fact is unknown.
Triple positivity for Abs, which is described by Vitorio 
Pengo’s group as being associated with high thrombotic 
recurrence rates in Italian APS patients, is also associated 
with high thrombotic recurrence rates in our cohort [22, 
23]. APS patients with triple positivity for Abs have sig-
nificantly higher MPV values than other APS patients. In 
multiple regression, the presence of LA and aβ2GPI con-
tributed to the prediction of the high MPV values in APS 
group with triple positivity for Abs.
We have also analysed the impact of the value of MPV 
on thrombosis recurrence in the analysed patients cohort 
with APS. A number of risk factors for arterial and/or 
venous thrombosis recurrence have already been defined 
[1, 24, 25]. Increased MPV has been noted in subjects with 
cardiovascular risk factors, such as smoking, diabetes, obe-
sity, hypertension and hyperlipidaemia [26]. The risk of 
thrombosis recurrence in our study in a univariate analysis 
Table 4  Univariate and multivariate analyses determining predictors for thrombosis recurrence in patients with APS
MPV mean platelet volume
Factor Univariate analysis OR (95 % CI), p Multivariate analysis OR (95 % CI), p
Male gender 1.83 (0.33–10.22), p = 0.338 0.65 (0.24–1.77), p = 0.394
Age 0.53 (0.06–4.84),  p = 0.562 0.99 (0.91–1.01), p = 0.823
Previous pulmonary embolism history 5.62 (1.07–29.42), p = 0.041 0.36 (0.09–1.44), p = 0.364
Hereditary thrombophilia 5.63 (1.08–29.41),  p = 0.040 3.328 (0.57–19.46), p = 0.182
Elevated factor VIII 1.02 (0.99–1.03),  p = 0.322 0.98 (0.94–1.01), p = 0.224
Elevated D-Dimer 1.01 (0.99–1.01),  p = 0.873 1.0 (0.998–1.00), p = 0.513
MPV ≥ 7.4 fl 42.25 (6.82–261.63), p = 0.001 3.65 (1.38–9.64), p = 0.009
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was significantly related to the value of MPV. Moreover, in 
the case of multivariate analysis, it was found that the prob-
ability of thrombosis recurrence was higher in the studied 
patients with APS. A level of MPV above 7.4 fl was iden-
tified as a prognostic factor of thrombosis recurrence in 
patients with APS.
Our results are in line with the study by Korkmaz et al. 
[27] on 22 patients with antiphospholipid syndrome and 22 
healthy controls that showed higher MPV in both patients 
with primary and secondary APS.
We found the coexistence of a moderate antithrombin 
deficiency with antiphospholipid syndrome in four cases. It 
may be a laboratory inaccuracy due to antithrombin inhibi-
tion by Abs [28].
Our study has several limitations. The number of study 
participants was limited. Besides, this was a one-centre 
study using one type of automated analyser. The use of dif-
ferent automated cell counters might influence measure-
ment and final results [29].
In conclusion, our study identifies the value of MPV as a 
prognostic factor of thrombosis recurrence in patients with 
APS. The results support the assumption that increased 
MPV could be an indirect indicator of platelet activation in 
patients with APS. In all likelihood, it may identify a group 
at the highest risk of thrombotic complications, as con-
firmed in our statistical analysis. The question of whether 
MPV may be a potentially useful prognostic biomarker for 
the prediction of recurrent venous or arterial thrombotic 
events in patients with antiphospholipid syndrome should 
be clarified in further prospective studies.
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